Sherwin-Williams Declares Dividend of $1.65 per Common Share; Board Approves Additional 15 Million Share Repurchase Authorization
Get Alerts SHW Hot Sheet
Join SI Premium – FREE
CLEVELAND, Feb. 17, 2021 /PRNewswire/ -- The Board of Directors of The Sherwin-Williams Company (NYSE: SHW) today announced a regular quarterly dividend of $1.65 per common share, an increase of 23.1% over the $1.34 paid in the same quarter in 2020, payable on March 12, 2021, to shareholders of record on March 1, 2021. This increase follows 42 consecutive years of dividend increases.
Also, the Board authorized the Company to purchase 15 million shares of the Company's common stock for treasury, which is in addition to the shares remaining under the existing share repurchase authorization announced in October 2015. The total amount authorized will be adjusted proportionately to reflect the three-for-one stock split announced on February 3, 2021 so that there will be three times as many shares authorized for repurchase immediately after the stock split. The repurchase authorization has no expiration date, and purchases may be made from time to time for general corporate purposes.
Investor Relations Contacts: | Media Contact: |
Jim Jaye | Julie Young |
Senior Vice President, Investor Relations & | Vice President, Global Corporate Communications |
Corporate Communications | Sherwin-Williams |
Sherwin-Williams | Direct: 216.515.8849 |
Direct: 216.515.8682 | |
Eric Swanson | |
Vice President, Investor Relations | |
Sherwin-Williams | |
Direct: 216.566.2766 | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/sherwin-williams-declares-dividend-of-1-65-per-common-share-board-approves-additional-15-million-share-repurchase-authorization-301230185.html
SOURCE The Sherwin-Williams Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Signia Introduces MaX, Powered by Acoustic Intelligence™: World's First AI Hearing Aid Platform with 4 DNNs
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
- Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From Ne
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Dividend, Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share